Skip to navigation Skip to content

News

Share

An FDA Approved Generic Form of Ampyra® (dalfampridine) Is Launched in the U.S.

October 19, 2018

A generic equivalent of Ampyra (dalfampridine), a treatment that is approved to improve walking in adults with MS, has been approved by the U.S. Food and Drug Administration and launched by Mylan NV. Dalfampridine extended-release tables 10 mg are currently available. Details on price have not been provided, but people with MS may qualify for a savings program.

Dalfampridine is approved by the FDA to improve walking in people with MS. Possible adverse events include seizures, urinary tract infection, nausea, dizziness, insomnia and upper respiratory tract infection. This approval means that Mylan provided evidence that this generic medication is equivalent to Ampyra.

Selecting a therapy should be done by people with MS in collaboration with their MS doctors, taking into account a variety of factors, including the effectiveness of any therapy they are currently using, and weighing potential risks and benefits, costs and lifestyle factors.

Read more
Read the dalfampridine medication guide for patients
View the dalfampridine prescription label
Find out if you qualify for the dalfampridine savings program
 
Frequently Asked Questions: Generic and Biosimilar - Medications

About Multiple Sclerosis

Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body. Symptoms range from numbness and tingling to blindness and paralysis. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS. Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease. MS affects more than 2.3 million people worldwide.

Share